JP2014528696A - 前立腺特異幹細胞抗原に対する抗体およびその使用 - Google Patents

前立腺特異幹細胞抗原に対する抗体およびその使用 Download PDF

Info

Publication number
JP2014528696A
JP2014528696A JP2014517736A JP2014517736A JP2014528696A JP 2014528696 A JP2014528696 A JP 2014528696A JP 2014517736 A JP2014517736 A JP 2014517736A JP 2014517736 A JP2014517736 A JP 2014517736A JP 2014528696 A JP2014528696 A JP 2014528696A
Authority
JP
Japan
Prior art keywords
antibody
seq
psca
cells
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528696A5 (enExample
Inventor
バッハマン・ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avencell Europe GmbH
Original Assignee
Gemoab GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab GmbH filed Critical Gemoab GmbH
Publication of JP2014528696A publication Critical patent/JP2014528696A/ja
Publication of JP2014528696A5 publication Critical patent/JP2014528696A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014517736A 2011-06-30 2012-06-29 前立腺特異幹細胞抗原に対する抗体およびその使用 Pending JP2014528696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6 2011-06-30
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017002983A Division JP6549622B2 (ja) 2011-06-30 2017-01-12 前立腺特異幹細胞抗原に対する抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2014528696A true JP2014528696A (ja) 2014-10-30
JP2014528696A5 JP2014528696A5 (enExample) 2015-10-01

Family

ID=46384405

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014517736A Pending JP2014528696A (ja) 2011-06-30 2012-06-29 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2017002983A Expired - Fee Related JP6549622B2 (ja) 2011-06-30 2017-01-12 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2019117977A Active JP6886491B2 (ja) 2011-06-30 2019-06-26 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2021081553A Active JP7341185B2 (ja) 2011-06-30 2021-05-13 前立腺特異幹細胞抗原に対する抗体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017002983A Expired - Fee Related JP6549622B2 (ja) 2011-06-30 2017-01-12 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2019117977A Active JP6886491B2 (ja) 2011-06-30 2019-06-26 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2021081553A Active JP7341185B2 (ja) 2011-06-30 2021-05-13 前立腺特異幹細胞抗原に対する抗体およびその使用

Country Status (18)

Country Link
US (1) US9200078B2 (enExample)
EP (2) EP3505536B1 (enExample)
JP (4) JP2014528696A (enExample)
AU (1) AU2012277784B2 (enExample)
CY (1) CY1121249T1 (enExample)
DE (1) DE102011118022B4 (enExample)
DK (1) DK2726507T3 (enExample)
ES (2) ES2989975T3 (enExample)
HR (1) HRP20190289T1 (enExample)
HU (1) HUE042008T2 (enExample)
LT (1) LT2726507T (enExample)
PL (1) PL2726507T3 (enExample)
PT (1) PT2726507T (enExample)
RS (1) RS58448B1 (enExample)
SI (1) SI2726507T1 (enExample)
SM (1) SMT201900085T1 (enExample)
TR (1) TR201901991T4 (enExample)
WO (1) WO2013001065A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
CN121673412A (zh) * 2024-09-12 2026-03-17 上海医药工业研究院有限公司 一种靶向psca的纳米抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511740A (ja) * 1997-03-10 2002-04-16 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｐｓｃａ：前立腺幹細胞抗原
JP2003515330A (ja) * 1999-10-29 2003-05-07 ジェネンテック・インコーポレーテッド 抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法
JP2007537714A (ja) * 2003-10-16 2007-12-27 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
JP2008500833A (ja) * 2004-05-28 2008-01-17 アジェンシス， インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
WO2010037835A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
JP2010538080A (ja) * 2007-09-04 2010-12-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511740A (ja) * 1997-03-10 2002-04-16 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｐｓｃａ：前立腺幹細胞抗原
JP2003515330A (ja) * 1999-10-29 2003-05-07 ジェネンテック・インコーポレーテッド 抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法
JP2007537714A (ja) * 2003-10-16 2007-12-27 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
JP2008500833A (ja) * 2004-05-28 2008-01-17 アジェンシス， インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
JP2010538080A (ja) * 2007-09-04 2010-12-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
WO2010037835A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EUR. J. NUCL. MED. MOL. IMAGING, vol. 37, no. 8, JPN5014008313, 1 April 2010 (2010-04-01), pages 1529 - 38, ISSN: 0003197508 *
INT. J. CANCER, vol. 82, JPN6016035794, 1999, pages 700 - 708, ISSN: 0003400336 *
J. CLIN. ONCOL., vol. Vol. 23, No. 16S, JPN6015046357, 2005, pages 4722, ISSN: 0003197506 *
PROC. NATL. ACAD. SCI., vol. 85, JPN6016035795, 1988, pages 7719 - 7723, ISSN: 0003400337 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 25, JPN6016035796, 2004, pages 26563 - 26570, ISSN: 0003400338 *
THE PROSTATE, vol. 71, no. 9, JPN5014008316, 15 June 2011 (2011-06-15), pages 998 - 1011, ISSN: 0003197507 *

Also Published As

Publication number Publication date
HUE042008T2 (hu) 2019-06-28
DK2726507T3 (en) 2019-03-11
HRP20190289T1 (hr) 2019-05-03
TR201901991T4 (tr) 2019-03-21
LT2726507T (lt) 2019-04-10
DE102011118022B4 (de) 2018-01-18
SI2726507T1 (sl) 2019-05-31
JP2017104113A (ja) 2017-06-15
RS58448B1 (sr) 2019-04-30
EP2726507B1 (de) 2018-11-21
WO2013001065A1 (de) 2013-01-03
ES2989975T3 (es) 2024-11-28
JP2019193652A (ja) 2019-11-07
JP6549622B2 (ja) 2019-07-24
JP7341185B2 (ja) 2023-09-08
PL2726507T3 (pl) 2019-06-28
CY1121249T1 (el) 2020-05-29
AU2012277784B2 (en) 2015-08-20
EP2726507A1 (de) 2014-05-07
EP3505536B1 (de) 2024-08-07
ES2711978T3 (es) 2019-05-08
EP3505536C0 (de) 2024-08-07
DE102011118022A1 (de) 2013-01-03
AU2012277784A1 (en) 2014-02-06
JP6886491B2 (ja) 2021-06-16
US9200078B2 (en) 2015-12-01
SMT201900085T1 (it) 2019-05-10
PT2726507T (pt) 2019-02-26
US20140134155A1 (en) 2014-05-15
JP2021121201A (ja) 2021-08-26
EP3505536A1 (de) 2019-07-03

Similar Documents

Publication Publication Date Title
JP7341185B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
US12421292B2 (en) Anti-DLL3 chimeric antigen receptors and uses thereof
AU2018241624B2 (en) Improved antigen binding receptors
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
US8759494B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
US11414497B2 (en) Anti-PSMA antibodies and use thereof
KR20180033501A (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
TW201704264A (zh) Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
KR102412805B1 (ko) 세포 면역 요법을 위한 조성물 및 방법
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
CN115335123A (zh) 人4-1bb激动剂抗体及其使用方法
CN114316050B (zh) Cd133抗体、嵌合抗原受体及其应用
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
CN116888154A (zh) Cea6结合分子及其用途
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150811

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160914